Evidence map›Paper›PMID 28114441›Full record

ArticleJAMA neurology2017

Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members.

Zongqi Xia, Sonya U Steele, Anshika Bakshi, Sarah R Clarkson, Charles C White, Matthew K Schindler, Govind Nair, Blake E Dewey, Lauren R Price, Joan Ohayon and 4 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in JAMA neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01353547 (Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01353547 recruitingnot on this map

Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility

TypeobservationalSponsorColumbia UniversityRan2017 to 2040Enrolled5,000ConditionsMultiple Sclerosis
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. The refined Pathways to Cures Research Roadmap for multiple sclerosis cures.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. The multiple sclerosis prodrome.Nature reviews. Neurology · 2021
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Zongqi XiaProgram in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts3Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts4Program in Translational Neurology and Neuroinflammation, Pittsburgh Institute of Neurodegenerative Diseases and Institute of Multiple Sclerosis Care and Research, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Sonya U SteeleDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Anshika BakshiDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Sarah R ClarksonProgram in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
Charles C WhiteProgram in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts3Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts.
Matthew K SchindlerDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Govind NairDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Blake E DeweyDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Lauren R PriceDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Joan OhayonDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Lori B ChibnikProgram in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts3Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts.
Irene C M CorteseDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
Philip L De JagerProgram in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts3Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts.
Daniel S ReichDivision of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.
National Institute of Neurological Disorders and Stroke · USBrigham and Women's Hospital · USBroad Institute · USUniversity of Pittsburgh · US

Funding

Multimodal MRI in Multiple SclerosisZIANS003119 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI REICH, DANIEL · 2010 to 2025
$53.4M
Leveraging electronic health records to optimize treatment selection and response in multiple sclerosisR01NS098023 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Zongqi Xia · 2016 to 2026
$4.6M
Leveraging genetics and environment to predict presymptomatic multiple sclerosisK08NS079493 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIA, ZONGQI · 2012 to 2016
$957k
Integrative analysis of genomic and epigenomic architecture in cognitive declineK25AG041906 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHIBNIK, LORI BETH · 2012 to 2016
$771k
Intramural NIH HHS Z99 NS999999Intramural NIH HHS ZIA NS003119NIA NIH HHS K25 AG041906NINDS NIH HHS K08 NS079493NINDS NIH HHS R01 NS098023
6 · The paper itself

Abstract

Importance: Subclinical inflammatory demyelination and neurodegeneration often precede symptom onset in multiple sclerosis (MS). Objective: To investigate the prevalence of brain magnetic resonance imaging (MRI) and subclinical abnormalities among asymptomatic individuals at risk for MS. Design, Setting, and Participants: The Genes and Environment in Multiple Sclerosis (GEMS) project is a prospective cohort study of first-degree relatives of people with MS. Each participant's risk for MS was assessed using a weighted score (Genetic and Environmental Risk Score for Multiple Sclerosis Susceptibility [GERSMS]) comprising an individual's genetic burden and environmental exposures. The study dates were August 2012 to July 2015. Main Outcomes and Measures: Participants in the top and bottom 10% of the risk distribution underwent standard and quantitative neurological examination, including disability status, visual, cognitive, motor, and sensory testing, as well as qualitative and quantitative neuroimaging with 3-T brain MRI and optical coherence tomography. Results: This study included 100 participants at risk for MS, with 41 at higher risk (40 women [98%]) and 59 at lower risk (25 women [42%]), at a mean (SD) age of 35.1 (8.7) years. Given the unequal sex distribution between the 2 groups, the analyses were restricted to women (n = 65). When considering all measured outcomes, higher-risk women differed from lower-risk women (P = .01 by omnibus test). Detailed testing with a vibration sensitivity testing device in a subgroup of 47 women showed that higher-risk women exhibited significantly poorer vibration perception in the distal lower extremities (P = .008, adjusting for age, height, and testing date). Furthermore, 5 of 65 women (8%) (4 at higher risk and 1 at lower risk) met the primary neuroimaging outcome of having T2-weighted hyperintense brain lesions consistent with the 2010 McDonald MRI criteria for dissemination in space. A subset of participants harbor many different neuroimaging features associated with MS, including perivenous T2-weighted hyperintense lesions and focal leptomeningeal enhancement, consistent with the hypothesis that these individuals are at higher risk of developing clinical symptoms of MS than the general population. Conclusions and Relevance: Higher-risk asymptomatic family members of patients with MS are more likely to have early subclinical manifestations of MS. These findings underscore the importance of early detection in high-risk individuals. Trial Registration: clinicaltrials.gov Identifier: NCT01353547.

Indexed as

Family HealthAdolescentAdultBrainChi-Square DistributionCohort StudiesDisability EvaluationFemaleHumansImaging, Three-DimensionalMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisNervous System DiseasesYoung Adult

Identifiers

PMID28114441
PMCPMC5348267
OpenAlexW2582193639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.